Hemogenyx Pharmaceuticals PLC (HEMO) — Financial Flexibility Index
Hemogenyx Pharmaceuticals PLC (HEMO) has a Financial Flexibility Index of -0.53x as of December 2024. Free cash flow of GBX-1.77 Million (operating CF GBX-1.78 Million minus capex GBX13.29K) represents -1% of total liabilities (GBX3.36 Million). Check Hemogenyx Pharmaceuticals PLC (HEMO) strategic asset index to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Hemogenyx Pharmaceuticals PLC Financial Flexibility Index (2015–2024)
Historical Financial Flexibility Index trend for Hemogenyx Pharmaceuticals PLC across 10 annual periods. See HEMO working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Hemogenyx Pharmaceuticals PLC (2015–2024)
Year-by-year free cash flow to debt coverage for Hemogenyx Pharmaceuticals PLC. For the full company profile including market capitalisation, see Hemogenyx Pharmaceuticals PLC (HEMO) market capitalisation.
| Year | Flexibility Index | Free Cash Flow (GBX) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.22x | GBX-4.10 Million | GBX-4.12 Million | GBX3.36 Million | ▲ +32.1% |
| 2023 | -1.80x | GBX-5.99 Million | GBX-6.11 Million | GBX3.32 Million | ▼ -179.3% |
| 2022 | -0.64x | GBX-2.48 Million | GBX-2.91 Million | GBX3.85 Million | ▲ +87.4% |
| 2021 | -5.13x | GBX-1.81 Million | GBX-2.63 Million | GBX352.84K | ▼ -464.4% |
| 2020 | -0.91x | GBX-1.63 Million | GBX-1.80 Million | GBX1.79 Million | ▼ -7.0% |
| 2019 | -0.85x | GBX-1.19 Million | GBX-1.20 Million | GBX1.40 Million | ▲ +14.3% |
| 2018 | -0.99x | GBX-1.33 Million | GBX-1.35 Million | GBX1.34 Million | ▲ +32.8% |
| 2017 | -1.47x | GBX-388.72K | GBX-452.98K | GBX263.69K | ▲ +23.8% |
| 2016 | -1.93x | GBX-277.96K | GBX-278.15K | GBX143.69K | ▼ -599099.8% |
| 2015 | 0.00x | GBX79.71 | GBX79.71 | GBX246.83K | — |